| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Product revenue, net | 206 | 98 | 120 | 168 |
| Restructuring costs | NaN | 194 | 0 | NaN |
| Cost of goods sold | 283 | 11 | 107 | 14 |
| Research and development | 2,955 | 8,740 | 10,256 | 4,554 |
| Selling, general and administrative | 7,191 | 5,381 | 5,609 | 5,699 |
| Total operating expenses | 10,429 | 14,326 | 15,972 | 10,267 |
| Loss from operations | -10,223 | -14,228 | -15,852 | -10,099 |
| Interest expense | 4,198 | 4,373 | 4,222 | 3,993 |
| Interest income | 211 | 236 | 230 | 279 |
| Other (income) expense, net | 1,519 | -12,546 | 657 | 6,559 |
| Net loss | -12,691 | -30,911 | -19,187 | -7,254 |
| Basic EPS | -0.54 | -2.18 | -2.45 | -1.5 |
| Diluted EPS | -0.54 | -2.18 | -2.45 | -1.5 |
| Basic Average Shares | 23,571,000 | 14,196,000 | 7,843,000 | 4,834,000 |
| Diluted Average Shares | 23,571,000 | 14,196,000 | 7,843,000 | 4,834,000 |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)